Press release
Investigation announced for Investors in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) over possible Wrongdoing
An investigation on behalf of investors in Travere Therapeutics, Inc. (NASDAQ: TVTX) shares over potential wrongdoing.
Investors who purchased shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Travere Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Travere Therapeutics, Inc. reported that its annual Total Revenue declined from $227.49 million in 2021 to $212.01 million in 2022, and that its Net Loss increased from $180.09 million in 2021 to $278.48 million in 2022.
Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) declined from $29.14 per share on August 08, 2022, to as low as $14.94 per share on July 17, 2023.
Those who purchased shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) over possible Wrongdoing here
News-ID: 3215877 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Treace Medical Concepts, Inc.
Investors who purchased shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Treace Medical Concepts, Inc. directors breached their fiduciary duties and caused damage to the company and its…
Deadline on May 20th coming up in Lawsuit for Investors in the Chemours Company …
A deadline is coming up on May 20, 2024 in the lawsuit filed for certain investors of The Chemours Company (NYSE: CC) over alleged securities laws violations by The Chemours Company.
Investors who purchased shares of The Chemours Company (NYSE: CC) have certain options and there are strict and short deadlines running. Deadline: May 20, 2024. NYSE: CC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
Lawsuit filed for certain Investors who lost money with shares of Global Cord Bl …
An investor, who purchased shares of Global Cord Blood Corporation (OTC: CORBF), filed a lawsuit over alleged violations of Federal Securities Laws by Global Cord Blood Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Global Cord Blood Corporation (OTC: CORBF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. OTC: CORBF investors should contact the Shareholders…
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ …
An investor, who purchased shares of Autodesk, Inc. (NASDAQ: ADSK), filed a lawsuit over alleged violations of Federal Securities Laws by Autodesk, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Autodesk, Inc. (NASDAQ: ADSK) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. NASDAQ: ADSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
More Releases for Travere
IgA Nephropathy Pipeline Assessment | Insights into the Current Therapies, Emerg …
As per DelveInsight's assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the IgA Nephropathy therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"IgA Nephropathy Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis…
Cystinuria Treatment Market is expected to grow at a CAGR of 6.00% during the fo …
Data Bridge Market Research analyzes that the Cystinuria Treatment Market will grow at a CAGR of roughly 6.00% during the forecast period 2021-2028. Growing demand for targeted therapies, increased research and development activities for the development of new drugs and therapies, and increased expenditures for the development of healthcare infrastructure are the major factors attributable to growth of the cystinuria treatment market.
Cystinuria is a rare inherited condition that causes…
IgA Nephropathy (IgAN) Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerg …
IgA Nephropathy pipeline constitutes 30+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analyzes DelveInsight
IgA nephropathy is one of the common forms of glomerulonephritis caused by the deposition of IgA immunoglobulin in the glomerular basement membrane. Immune-mediated damage to the basement membrane results in hematuria and renal insufficiency. Berger was the first to describe the disease, so it also carries the name Berger disease.
"IgA Nephropathy (IgAN) Pipeline…
Focal Segmental Glomerulosclerosis Market is Projected to Grow During the Foreca …
The Focal Segmental Glomerulosclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Focal Segmental Glomerulosclerosis market dynamics.
DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology, as well as the Focal Segmental Glomerulosclerosis market trends…
IgA Nephropathy Drugs market: Leading Market Trends to Look for in 2022 | Callid …
"
The IgA Nephropathy Drugs global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key…
Global Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report …
Vasculitis Pipeline constitutes 30+ key companies continuously working towards developing 30+ Vasculitis treatment therapies, analyzes DelveInsight
DelveInsight's 'Vasculitis Pipeline Insight 2022' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Vasculitis pipeline domain.
Find a sample copy of the Vasculitis Pipeline report - https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kupr
Some of the essential takeaways…
